Market closed
Corcept Therapeutics/$CORT
Corcept Therapeutics shares are trading higher after announcing positive trial results for an ovarian cancer drug, expanding its potential patient base and revenue.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Ticker
$CORT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
500
Website
CORT Metrics
BasicAdvanced
$7.3B
56.32
$1.23
0.58
-
Price and volume
Market cap
$7.3B
Beta
0.58
52-week high
$117.33
52-week low
$22.00
Average daily volume
2M
Financial strength
Current ratio
3.35
Quick ratio
3.106
Long term debt to equity
0.899
Total debt to equity
1.021
Management effectiveness
Return on assets (TTM)
11.71%
Return on equity (TTM)
23.81%
Valuation
Price to earnings (TTM)
56.317
Price to revenue (TTM)
10.593
Price to book
10.71
Price to tangible book (TTM)
10.71
Price to free cash flow (TTM)
36.504
Growth
Revenue change (TTM)
39.94%
Earnings per share change (TTM)
30.85%
3-year revenue growth (CAGR)
22.64%
3-year earnings per share growth (CAGR)
11.39%
What the Analysts think about CORT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
CORT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CORT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CORT News
AllArticlesVideos
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
Business Wire·2 days ago
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss
Seeking Alpha·2 days ago
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder
Seeking Alpha·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Corcept Therapeutics stock?
Corcept Therapeutics (CORT) has a market cap of $7.3B as of April 25, 2025.
What is the P/E ratio for Corcept Therapeutics stock?
The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 56.32 as of April 25, 2025.
Does Corcept Therapeutics stock pay dividends?
No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Corcept Therapeutics dividend payment date?
Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Corcept Therapeutics?
Corcept Therapeutics (CORT) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.